NCT04979975View on ClinicalTrials.gov

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Recurrent Genital Herpes
Interventions
OTHER

Placebo

PBO- placebo matching to UB-621

BIOLOGICAL

UB-621 low-dose

fully human anti-HSV mAb

BIOLOGICAL

UB-621 high-dose

fully human anti-HSV mAb

All Listed Sponsors
lead

UBP Greater China (Shanghai) Co., Ltd

INDUSTRY